Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
1.
Acta Pharmaceutica Sinica ; (12): 986-992, 2015.
Article Dans Chinois | WPRIM | ID: wpr-257037

Résumé

The aim of this study is to investigate the anti-inflammatory effect of the adenosine derivative N6-(3-hydroxylaniline) adenosine (WS070117M1) on cigarette smoke plus LPS (lipopolysaccharide)-induced chronic obstructive pulmonary disease (COPD) in mice and its mechanism. COPD model was established by exposing male BALB/c mice to cigarette smoke and challenged with LPS inhalation. Supernatants of bronchoalveolar lavage fluid (BALF) were harvested and IL-1β, IL-6, IL-8 and TGF-β1 levels were measured by ELISA (enzyme-linked immunesorbent assay). The number of total white blood cells and neutrophils in bronchoalveolar lavage fluid was counted separately. Lung tissue was stained with Mayer 's hematoxylin and eosin for histopathologic examination. pAMPKa protein expression and distribution of lung tissue were analyzed by immunohistochemistry method. In vitro, levels of AMPKα phosphorylation in phorbol-12- myristate-13-acetate (PMA) differentiated THP-1 cells was detected by immunohistochemistry, IL-8 level in supernatants of cigarette smoke condensate stimulating PMA differentiated THP-1 cells was measured by ELISA. The results showed that WS070117M1 treatment significantly activated AMPKa in the lung tissue. It also resulted in down regulation of IL-1β, IL-6, IL-8 and TGF-β1 levels in bronchoalveolar lavage fluid and IL-8 level in cigarette smoke condensate stimulating PMA differentiated THP-1 cells. In addition, WS070117M1 could inhibit the recruitment of total white blood cells and neutrophils. These results suggest that WS070117M1 may alleviate the airway inflammation by activating AMPK in the lung tissue.


Sujets)
Animaux , Humains , Mâle , Souris , AMP-Activated Protein Kinases , Métabolisme , Adénosine , Liquide de lavage bronchoalvéolaire , Lignée cellulaire tumorale , Modèles animaux de maladie humaine , Inflammation , Traitement médicamenteux , Interleukine-1 bêta , Métabolisme , Interleukine-6 , Métabolisme , Interleukine-8 , Métabolisme , Numération des leucocytes , Lipopolysaccharides , Souris de lignée BALB C , Granulocytes neutrophiles , Biologie cellulaire , Broncho-pneumopathie chronique obstructive , Traitement médicamenteux , Fumée , Nicotiana , Facteur de croissance transformant bêta-1 , Métabolisme
2.
Acta Pharmaceutica Sinica ; (12): 1183-1188, 2013.
Article Dans Chinois | WPRIM | ID: wpr-259495

Résumé

P2X7 is the most important subtype of the ATP receptors known so far. Recent investigations showed that the downstream signaling pathway of P2X7 is coupled with several key inflammatory molecules including IL-1beta and IL-18, this suggests P2X7 might have roles in the inflammatory diseases. Moreover, attenuation of P2X7 by selective antagonists in vitro and knockout mice in vivo reducing the inflammatory response indicated that P2X7 is a potential therapeutic target for inflammatory diseases. However, most previous studies on P2X7 were focused on nerve system diseases most, while its effects in inflammatory respiratory diseases, especially in asthma, chronic obstructive pulmonary disease (COPD) and lung cancer have been poorly investigated. In this paper, we reviewed the research progress on the structure, distribution, biological activities of P2X7 and its relationship with inflammatory respiratory diseases including asthma, COPD and lung cancer, along with the development of P2X7 antagonist as therapeutics.


Sujets)
Animaux , Humains , Souris , Asthme , Traitement médicamenteux , Métabolisme , Inflammation , Traitement médicamenteux , Métabolisme , Interleukine-18 , Métabolisme , Interleukine-1 bêta , Métabolisme , Tumeurs du poumon , Traitement médicamenteux , Métabolisme , Polymorphisme de nucléotide simple , Broncho-pneumopathie chronique obstructive , Traitement médicamenteux , Métabolisme , Antagonistes des récepteurs purinergiques P2X , Utilisations thérapeutiques , Récepteurs purinergiques P2X7 , Chimie , Génétique , Métabolisme , Maladies de l'appareil respiratoire , Traitement médicamenteux , Métabolisme
3.
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 681-684, 2012.
Article Dans Chinois | WPRIM | ID: wpr-252535

Résumé

<p><b>OBJECTIVE</b>To observe the effects of Modified Liangge Powder (MLP) on the expressions of platelet toll like receptor 4 (TLR4) and the release of platelet-derived cytokines interleukin 8 (IL-8), beta platelet globulin (beta-TG), soluble CD40 ligand (sCD40L).</p><p><b>METHODS</b>The modulating effects on the release of cytokines from mice platelets by TLR4 ligand through monoclonal antibody blocking TLR4 on platelet were compared. The stimulated platelet by LPS was incubated with low (0.94 g/mL), medium (1.89 g/mL), and high (2.84 g/mL) dose of MLP contained serum. The changes of the platelet TLR4 expression and platelet-derived cytokines were observed.</p><p><b>RESULTS</b>The positive expression rate of platelet TLR4 obviously decreased (P < 0.01) and the release of sCD40L and beta-TG from platelets significantly increased (P < 0.01) after stimulated by LPS. However, the release of sCD40L and beta-TG from platelets obviously decreased by TLR4 monoclonal antibody (P < 0.05, P < 0.01). There was no statistical difference in IL-8 between before and after LPS stimulation (P > 0.05). Platelet TLR4 positive expression rate was significantly higher after incubated by medium and high doses of MLP contained serum (P < 0.01), and the releasing of sCD40L and beta-TG was lower in the serum contained groups. The inhibitory effects were enhanced in a dose-dependent manner.</p><p><b>CONCLUSIONS</b>LPS induced platelet activation by TLR4 and released sCD40L and beta-TG, while the release of platelet IL-8 was not dependent on platelet TLR4-LPS pathway. MLP could inhibit LPS-stimulated sCD40L and beta-TG, inhibit the binding of platelet TLR4 and LPS in a dose-dependent manner, thus reducing the release of platelet cytokines.</p>


Sujets)
Animaux , Mâle , Souris , bêta-Globulines , Métabolisme , Plaquettes , Métabolisme , Ligand de CD40 , Métabolisme , Cytokines , Métabolisme , Médicaments issus de plantes chinoises , Pharmacologie , Interleukine-8 , Métabolisme , Lipopolysaccharides , Souris de lignée ICR , Sérum , Récepteur de type Toll-4 , Métabolisme
4.
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 214-217, 2005.
Article Dans Chinois | WPRIM | ID: wpr-284475

Résumé

<p><b>OBJECTIVE</b>To observe the therapeutic effect of Shennong No. 33 (SN33) in treating multiple organ dysfunction syndrome (MODS) by APACHE II and APACHE II scoring.</p><p><b>METHODS</b>One hundred and twenty-nine patients of MODS were randomly divided into the treated group (n = 72) and the control group (n = 57), they were treated with comprehensive therapy and to the treated group, SN33 was given additionally. The changes of APACHE II and APACHE III scores and blood endotoxin level were observed at the time points of within 24 hrs after hospitalization, and the 3rd, 5th and 7th day.</p><p><b>RESULTS</b>In the treated group, 50 patients survived and 22 died, while in the control group, 25 survived and 32 died. The APACHE II and APACHE III scores of the survivors were higher than those of the decedent (P<0.05), which in the treated group was lower than those in the control group (P<0.05). The blood level of endotoxin in the treated group was also lower than that in the control group (P<0.05).</p><p><b>CONCLUSION</b>SN33 in treating MODS could improve patients' condition, lead to the lowering of APACHE scores. APACHE scoring system could be applied as the criteria for evaluating the condition and prognosis of critical patients, and the APACHE III scoring is more accurate.</p>


Sujets)
Adolescent , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Indice APACHE , Antibactériens , Utilisations thérapeutiques , Association de médicaments , Médicaments issus de plantes chinoises , Utilisations thérapeutiques , Endotoxines , Sang , Défaillance multiviscérale , Traitement médicamenteux , Phytothérapie
SÉLECTION CITATIONS
Détails de la recherche